PBI 4050

Drug Profile

PBI 4050

Alternative Names: PBI-4050

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Developer ProMetic Life Sciences; Vanderbilt University
  • Class Anti-inflammatories; Antifibrotics; Small molecules
  • Mechanism of Action Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Extracellular matrix protein modulators; Immunomodulators; Inflammation mediator inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Inborn genetic disorders; Metabolic syndrome
  • Preclinical Pulmonary arterial hypertension; Renal fibrosis; Scleroderma
  • No development reported Anaemia; Haematological disorders; Neutropenia

Most Recent Events

  • 18 Apr 2017 Chemical structure information added
  • 30 Mar 2017 Prometic Life Sciences and Shenzhen Royal Asset Management enter agreement to form joint venture company for development, manufacturing and commercialisation of PBI 4050
  • 03 Mar 2017 PBI 4050 receives Orphan Drug status for Inborn genetic disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top